The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective

Table 2

Base-case and key scenario results.

	Incremental costs	Incremental QALYs	Incremental LYs	Incremental progression-free years	ICUR
Base-case	–$5,021	0.17	0.22	0.34	Dominant
Key scenarios
(1) 5% sorafenib price reduction	–$3,770	0.17	0.22	0.34	Dominant
(2) 10% sorafenib price reduction	–$2,518	0.17	0.22	0.34	Dominant
(3) 15% sorafenib price reduction	–$1,267	0.17	0.22	0.34	Dominant
(4) Adjustment for postprogression therapies and regorafenib only postprogression	–$9,472	0.22	0.29	0.34	Dominant
(5) Scenarios 3 and 4 combined	–$5,222	0.22	0.29	0.34	Dominant

Abbreviations: ICUR, incremental cost-utility ratio; Lys, life years; QALYs, quality-adjusted life years.